KCNT1 Families meet with the FDA in a Patient Listing Session

On April 22, 2024, the KCNT1 Epilepsy Foundation held a Patient-led Listening Session with the Food and Drug Administration. The objective of the session was to provide FDA staff with the opportunity to hear about the lives of patients and families living with KCNT1-related epilepsy, the urgent need for treatments, what caregivers feel would be meaningful treatment outcomes and their risk tolerance to obtain those outcomes. You can read the summary here.